EntreMed to Raise $10.7m in Registered Direct Offering

EntreMed has received commitments from investors, including institutional investors Kleiner Perkins Caufield Byers China Fund II L.P. and IDG-Accel China Growth Fund III L.P. to purchase approximately $10.7 million of securities in a registered direct offering. EntreMed is a clinical-stage pharmaceutical company employing a drug development strategy primarily in the United States and China to develop targeted therapeutics for the global market.

North AmericaUSBriefs